Suven Life Sciences Limited (SUVEN)

Loading page…

Suven Life Sciences Limited (SUVEN) · mywealthgrid

About

Suven Life Sciences operates in healthcare research, analytics, and technology within India's healthcare services sector. At ₹9,038 Cr market cap, it is a small-cap player with quarterly revenues ranging from ₹0.92–₹3.57 Cr, positioning it as an early-stage or niche service provider rather than a scaled player.

Founded: 1989
Face value: ₹1

Market cap

₹8,139 Cr

P/E

—

P/B

13.7×

Dividend yield

ROE

-78.8%

ROCE

-78.4%

Debt / equity

OPM

—

EPS (TTM)

₹-13.4

Book value

₹22.4

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Consistent net losses across all recent quarters (Sep 2025–Jun 2026), with negative operating margins of -529% to -588% where calculable, raising questions about unit economics and business model viability.
Sharply negative ROE of -78.8% indicates the company is destroying shareholder capital; verify what investments are being made and when management expects profitability.
Quarterly revenue base of under ₹4 Cr is very small; clarify market size addressable, current client wins, and revenue trajectory needed to reach scale and profitability.
Stock returned 29.68% over 1 year despite persistent losses—verify what catalyst or forward guidance is driving valuation, as momentum reversal poses downside risk.

Generated analysis · source review pending

Growth drivers

Healthcare research services demand in India: verify whether the company has signed contracts, expanded client base, or gained share in the addressable market that would justify the revenue base moving above ₹3–4 Cr/quarter.
Operating-margin expansion if revenue scales: at ₹0.92–3.57 Cr quarterly, the company may be pre-scale; verify unit costs and fixed-cost base to assess leverage potential.
Acquisition as a research capability: promoters hold 70%, and institutional interest is minimal (FII 0.57%, DII 2.93%); verify whether the company is exploring sale or partnership to larger healthcare or pharma groups.
Debt-free balance sheet (D/E = 0) provides flexibility to invest, acquire, or sustain losses; verify capital allocation plans and cash runway.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹308.3-5.1%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+High promoter holding of 70.1% with no pledge

Cons

−Low return on equity of -65.3% (3-yr avg)
−Revenue shrank over the last 5 years (-12% a year)
−Weak interest coverage of -1726.2×
−Trading at 13.7× book value

Research score

Structured signal from quality, growth, valuation and momentum.

42/100

Business quality: 25
Growth: 50
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	544	625	14	13	12	14	12	7	7
COGS	152	154	0	0	0	0	0	0	0
Gross profit	393	472	—	—	—	—	—	—	—
	264	273	130	94	134	139	140	172	292
	129	198	-116	-80	-122	-126	-128	-166	-285
OPM %	23.7%	31.7%	-803.1%	-593.9%	—	-929.8%	-1,095%	—	—
Depreciation	21	21	4	4	4	7	7	6	6
Interest	6	5	1	1	1	0	0	0	0
	21	23	14	8	5	14	29	11	14
Profit before tax	123	196	-106	-77	-122	-118	-106	-161	-276
Tax	36	72	-12	-5	0	0	-1	0	0
Tax %	29.2%	36.7%	-11.5%	-6.9%	0%	0%	-0.9%	0%	0%
	87	124	-94	-72	-122	-118	-105	-161	-276
PAT margin %	16%	19.8%	-653.9%	-535.2%	—	-873.5%	-898.9%	—	—
EPS (₹)	—	9.7	-2	-5.7	-9.6	-6.6	-4.8	-7.4	-12.1
EPS adjusted (₹)	6.9	9.7	-7.4	-5.7	-8.4	-5.4	-4.8	-7.4	-10.5
	—	15.5%	—	—	—	—	—	—	—
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	13	13	13	13	13	13	15	22	22	22	26
Reserves	551	654	755	226	131	95	82	354	248	88	565
	88	56	33	2	1	1	0	0	0	0	0
	94	92	119	62	38	19	11	14	15	25	33
Total equity & liabilities	746	816	919	303	182	128	108	389	285	135	624
	172	306	308	23	21	21	38	37	28	60	56
CWIP	107	10	25	0	0	5	4	0	0	0	4
Investments	23	301	279	223	0	0	45	46	76	22	0
	444	199	308	58	161	103	22	305	181	53	565
Total assets	746	816	919	303	182	128	108	389	285	135	624

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	75.4%	—	—	—	—	—	—	—
EBITDA margin %	31.7%	-803.1%	-593.9%	-1,033.8%	-929.8%	-1,095%	-2,489%	-4,001.5%
EBIT margin %	28.3%	-832%	-626.2%	-1,070.9%	-978.1%	-1,150.6%	-2,576.4%	-4,080.5%
PAT margin %	19.8%	-653.9%	-535.2%	-1,030.4%	-873.5%	-898.9%	-2,413.5%	-3,886.6%
Working capital
Receivable days	36	57	48	40	22	40	73	78
Inventory days	331	—	1	0	0	2	1	0
Payable days	—	—	12	5	4	5	11	6
NWC days	—	—	36	35	17	37	63	72
Leverage
Current ratio	4.69	2.49	6.45	8.01	22.6	18.98	3.21	17.69
Debt to EBITDA	0.17	—	—	—	—	—	—	—
Debt to equity	0.04	0.01	0.01	0	0	0	0	0
Interest coverage	43.2	-192.5	-93.5	-229.2	-427.5	-708.6	-3,213.8	-1,726.2
Asset turnover	0.68	0.08	0.1	0.11	0.03	0.04	0.05	0.01
Return ratios
Return on assets %	13.5%	-51.8%	-56.2%	-112.9%	-30.4%	-36.9%	-118.9%	-44.3%
Return on capital employed %	26.8%	-22.2%	-57.2%	-114.5%	-51.9%	-34.9%	-83.9%	-78.4%
Return on equity %	16.1%	-65.7%	-66.8%	-126.9%	-31.5%	-38.9%	-146.1%	-46.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	69.57%	69.57%	69.57%	70.27%	70.27%	70.27%	70.27%	70.27%	67.36%	67.36%	70.15%	70.08%
	0.5%	0.54%	0.46%	0.45%	0.34%	0.34%	0.25%	0.59%	1.18%	1.07%	0.91%	0.57%
	0.01%	0.12%	1.17%	1.17%	1.05%	1.06%	0.01%	0.02%	3.39%	3.39%	4.62%	2.93%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	29.92%	29.77%	28.8%	28.11%	28.34%	28.33%	29.47%	29.12%	28.07%	28.18%	24.32%	26.42%
No. of shareholders	—	—	—	—	—	—	—	—	64,921	64,381	63,915	66,791

Promoter holding up 0.51 percentage points since Sep 2023.

4 deals · 13 Sept 2023 – 11 Jan 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
11 Jan 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	14,28,543	₹121.70	₹17.39 Cr
11 Jan 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	14,28,543	₹121.82	₹17.40 Cr
13 Sept 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	15,34,944	₹78.20	₹12.00 Cr
13 Sept 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	15,34,944	₹78.12	₹11.99 Cr

1–4 of 4

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. VENKATESWARLU JASTIExecutive Director-Chairperson-MD
Mrs. SUDHARANI JASTIExecutive Director
Mr. SEYED EHTESHAM HASNAINNon-Executive - Non Independent Director
Mr. SANTANU MUKHERJEENon-Executive - Independent Director
Mrs. ANANTHASAI PADMAJA JASTHINon-Executive - Independent Director
Mr. VAJJA SAMBASIVA RAONon-Executive - Independent Director
Mohan M KumarChief Financial Officer
Ms. Sangeetha Laxmi KandariCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

0.01%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

2 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	2,026	0.08	0.18%	0.001%	+3
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	219	0.01	0.01%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

15

Interim dividend14 Feb 2019 · ex-date₹1.5
Interim dividend6 Feb 2018 · ex-date₹1.5
Interim dividend8 Feb 2017 · ex-date₹1
Interim dividend14 Mar 2016 · ex-date₹1
Special dividend14 Mar 2016 · ex-date₹1
Dividend dividend23 Jul 2015 · ex-date₹0.6
Special dividend24 Jul 2014 · ex-date₹2
Dividend dividend24 Jul 2014 · ex-date₹0.5
Dividend dividend1 Aug 2013 · ex-date₹0.3
Dividend dividend17 Sept 2012 · ex-date₹0.3
Dividend dividend1 Aug 2011 · ex-date₹0.25
Dividend dividend19 Jul 2010 · ex-date₹0.25
Dividend dividend14 Sept 2009 · ex-date₹0.25
Dividend dividend11 Sept 2008 · ex-date₹0.25
Dividend dividend21 Sept 2007 · ex-date₹0.25

1

Board meeting to consider results6 Aug 2026

1

Bonus 1:123 Mar 2007 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

66 announcementsExport CSV

28 Sept 2026, 2:17 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

3 Sept 2026, 11:56 amCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

25 Aug 2026, 6:27 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

25 Aug 2026, 6:24 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

11 Aug 2026, 12:33 pmCompany Update

Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Monitoring Agency Report PDF

7 Aug 2026, 12:36 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

31 Jul 2026, 2:08 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

30 Jul 2026, 3:35 pmBoard Meeting

Board Meeting Intimation for Consideration Of Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June, 2026

Exchange filing PDF

Date	Category	Subject	Filing
28 Sept 2026, 2:17 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
3 Sept 2026, 11:56 am	Company Update Press Release / Media Release	Announcement under Regulation 30 (LODR)-Press Release / Media Release	PDF

Loading announcements…

Ratio	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	75.4%	—	—	—	—	—	—	—
EBITDA margin %	31.7%	-803.1%	-593.9%	-1,033.8%	-929.8%	-1,095%	-2,489%	-4,001.5%
EBIT margin %	28.3%	-832%	-626.2%	-1,070.9%	-978.1%	-1,150.6%	-2,576.4%	-4,080.5%
PAT margin %	19.8%	-653.9%	-535.2%	-1,030.4%	-873.5%	-898.9%	-2,413.5%	-3,886.6%
Working capital
Receivable days	36	57	48	40	22	40	73	78
Inventory days	331	—	1	0	0	2	1	0
Payable days	—	—	12	5	4	5	11	6
NWC days	—	—	36	35	17	37	63	72
Leverage
Current ratio	4.69	2.49	6.45	8.01	22.6	18.98	3.21	17.69
Debt to EBITDA	0.17	—	—	—	—	—	—	—
Debt to equity	0.04	0.01	0.01	0	0	0	0	0
Interest coverage	43.2	-192.5	-93.5	-229.2	-427.5	-708.6	-3,213.8	-1,726.2
Asset turnover	0.68	0.08	0.1	0.11	0.03	0.04	0.05	0.01
Return ratios
Return on assets %	13.5%	-51.8%	-56.2%	-112.9%	-30.4%	-36.9%	-118.9%	-44.3%
Return on capital employed %	26.8%	-22.2%	-57.2%	-114.5%	-51.9%	-34.9%	-83.9%	-78.4%
Return on equity %	16.1%	-65.7%	-66.8%	-126.9%	-31.5%	-38.9%	-146.1%	-46.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Syngene International LimitedSYNGENESYNGENE	₹14,586 Cr	₹14,595 Cr	₹3,600 Cr	₹803 Cr	24.6%	₹221 Cr	8.5%	9.8%	6.6%	-32
Indegene LimitedINDGNINDGN	₹14,303 Cr	₹14,303 Cr	₹3,813 Cr	₹638 Cr	17.6%	₹401 Cr	11.4%	17.9%	13.9%	79
Suven Life Sciences LimitedSUVENSUVEN	₹8,139 Cr	₹8,139 Cr	₹9 Cr	₹-366 Cr	—	₹-352 Cr	—	-78.4%	-78.8%	72
Vimta Labs LimitedVIMTALABSVIMTALABS	₹2,612 Cr	₹2,631 Cr	₹336 Cr	₹112 Cr	27.3%	₹61 Cr	12.9%	17.4%	13.6%	179
Bilcare LimitedBIBI	₹227 Cr	₹896 Cr	₹788 Cr	₹45 Cr	5.7%	₹-29 Cr	-7.1%	1.5%	-6%	78
Take Solutions LimitedTAKETAKE	₹187 Cr	₹187 Cr	₹85 Cr	₹-2 Cr	-3.5%	₹13 Cr	20%	18.5%	42.1%	-7
Jeevan Scientific Technology LtdJSTLJSTL	₹169 Cr	₹186 Cr	₹62 Cr	₹10 Cr	16%	₹0 Cr	1.7%	5.4%	1.7%	-109
Novelix Pharmaceuticals LtdNOVELIXNOVELIX	₹167 Cr	₹167 Cr	₹9 Cr	₹-3 Cr	-29.9%	₹-2 Cr	-23.6%	-28.1%	-28.5%	57
Globalspace Technologies LtdGSTLGSTL	₹103 Cr	—	₹25 Cr	₹11 Cr	5.9%	₹7 Cr	-1.4%	—	—	—
Adeshwar Meditex LtdADESHWARADESHWAR	₹23 Cr	—	₹56 Cr	₹3 Cr	4.9%	₹1 Cr	2.3%	—	—	—
Vanta Bioscience LtdVANTABIOVANTABIO	₹15 Cr	—	₹2 Cr	₹1 Cr	56.6%	₹0 Cr	6%	—	—	—

₹ Cr	Mar 2016	Mar 2017	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	68	109	-133	-128	-208	-83	-154	-302
	-39	-311	93	-22	-156	62	155	-462
	-68	-30	35	146	396	-1	-1	757
Net cash flow	-39	-232	-5	-4	32	-22	0	-7
Free cash flow	—	—	-139	-147	-211	-85	-191	-307
CFO / Operating profit %	—	84.3%	—	—	—	—	—	—

Suven Life Sciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Events

Dividends15

Board meetings1

Bonus issues1

Announcements

Dividends15

Board meetings1

Bonus issues1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

15

1

1

15

1

1